ZURICH (Reuters) - Roche on Monday said its Foundation Medicine unit won U.S. Food and Drug Administration (FDA) approval for a test to help doctors understand the genetic profile of patients’ tumors and guide them to effective therapies.
Roche, which owns 58 percent of Foundation, is hoping to use the FoundationOne CDx assay to personalize cancer care, where treatment is better tailored to the specific molecular characteristics of each patient’s disease.
Reporting by John Miller
